Akorn Pharmaceutical company

Endo Pharmaceutical (ENDP - Get Report)  was tumbling Monday after being downgraded to underweight from neutral with a price target of $9 by JPMorgan analyst Christopher T. Schott.

The stock fell 14.33% to $6.91. Its 52-week range is $5.79 to $18.50. Its consensus target price is $12.67. 

There are 10 holds, one sell, one overweight and three buy ratings on the stock.

Along with Teva (TEVA - Get Report) , Endo was cited in an ongoing price-fixing civil suit and opioid litigation. A new generics-pricing lawsuit was filed by more than 40 states targeting 17 generic drugmakers or their subsidiaries. Endo faces shared liability of more than 100 drugs, which puts billions of dollars in exposure.

A spokesman for Teva Pharmaceuticals USA said the company hasn't engaged in any conduct that would lead to civil or criminal liability.

"The allegations in this new complaint, and in the litigation more generally, are just that - allegations," Kelley Dougherty, a Teva vice president, said in a statement Saturday.
 
Teva shares fell 15.9% on Monday to $12.08.

On a brighter note, Endo an earnings and revenue beat last week. First-quarter earnings were 53 cents a share vs. Zacks Consensus Estimate of 42 cents. Revenue was $720.4 million vs. consensus $692.2 million, according to Zacks.

Endo has a market cap of $1.562 billion; Teva's is $13.19 billion.